Dendritic Cell-Based Vaccines Positively Impact Natural Killer and Regulatory T Cells in Hepatocellular Carcinoma Patients
Figure 1
CD69 and CD25 expression on CD56loCD16+ and CD56hiCD16− NK cells. Phenotyping of NK cells from patients who received the AFP pep/DC vaccine, showing longitudinal changes. “Pre” denotes PBMC from time point 0. DC vaccines were delivered (after blood draws) on days 0, 14, and 28. “Post” denotes PBMC from postvaccine administration at time points available in the remaining batched PBMC. Patient A1 tested at days 35 and 56 (7 days and 28 days after the third vaccine); pt B2 at d28, 56, and 112; pt B5 at d14 and 28; pt B8 and d14 and 112, pt A4 at d14. CD69 and CD25 markers (by MFI) are shown for both NK cell subsets. Percent positivity is shown in Supplementary Figure 2. One-tail t-test values are: CD56loCD16+CD69 MFI: pre to post 1: 0.05; pre to post 2: 0.03; post 1 to post 2: 0.16; all other values higher and not significant (n.s.). CD56hiCD16−CD69 MFI: pre to post 1: 0.07, all other values higher and n.s. CD56loCD16+CD25 MFI: pre to post 1: 0.05, pre to post 2: 0.11, post 1 to post 2: 0.12, all other values higher and n.s. CD56loCD16−CD25 MFI: pre to post 1: 0.04, pre to post 2: 0.15, all other values higher and n.s.